2026
- Skyhawk Therapeutics Community Letter: An Update for the Huntington’s Disease Community on SKY-0515
- Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
- Huntington’s Disease Society of America Welcomes Three New Members to its Board of Trustees
- uniQure AMT-130 HD Community Letter
- uniQure Announces Type A Meeting Scheduled with FDA
